Peri-operative cardiac protection for non-cardiac surgery

Area of Science:

• Anesthesiology
• Cardiology
• Peri-operative Medicine

Background:

• Cardiovascular complications significantly contribute to morbidity and mortality post-non-cardiac surgery.
• Effective peri-operative management is key to mitigating these risks.

Purpose of the Study:

• To review the evidence on peri-operative medications for cardiovascular risk reduction in non-cardiac surgery.
• To provide guidance on the use of beta-blockers, statins, aspirin, and anesthetic agents.

Main Methods:

• Review of existing literature and clinical studies on peri-operative cardiovascular risk management.
• Analysis of the impact of specific medications (beta-blockers, statins, aspirin, alpha-2 agonists) and anesthetic agents on cardiovascular outcomes.

Main Results:

• Continuation of chronic beta-blocker and statin therapy is recommended.
• Peri-operative statin initiation may benefit high-risk patients and those undergoing vascular surgery.
• Pre-operative beta-blocker introduction reduces myocardial injury but may increase stroke and mortality; use requires careful titration.
• Aspirin continuation increases bleeding risk; nitrous oxide's risk of myocardial injury is not confirmed.
• Cardioprotective effects of volatile anesthetics and opioids are not conclusively proven in clinical settings.

Conclusions:

• Continue chronic beta-blocker and statin therapy.
• Use beta-blockers cautiously in high-risk patients, titrating dose to heart rate.
• Consider peri-operative statin initiation for high-risk patients and vascular surgery patients.
• Careful consideration of aspirin and anesthetic agents is needed based on individual patient risk profiles.